Key Takeaways:
- IM8 closed $1 billion in growth financing from General Catalyst’s Customer Value Fund.
- Launched in November 2024, IM8 has had soccer star David Beckham as a co-founder and equity stakeholder since inception.
- IM8 has scaled from zero to over $200 million in annualized run-rate revenue within its first 19 months of operations.
Prenetics’ IM8 secured $1 billion in growth financing from General Catalyst’s Customer Value Fund (CVF).
WHO: Launched in 2024, IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner and an elite team of scientists spanning medical professionals, academia, and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials Pro, is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors, or sweeteners. IM8 is a subsidiary of Prenetics, a leading consumer health company on a mission to advance human health and longevity.
WHY: The rationale for the CVF partnership is structural rather than liquidity driven. Historically, high-growth consumer businesses have faced a binary choice when scaling customer acquisition: raise dilutive equity capital, or hold back on growth to preserve cash reserves. The Customer Value Fund represents a third way: no-dilution, risk-aligned, cohort-matched capital purpose-built to finance customer...
